Phase I/II, Open Label, Randomized, Safety and Immunogenicity Following DTwP-Hepatitis B-Hib-IPV Vaccine (Bio Farma) in Indonesian Infants

This trial is open label, comparative, randomized, phase I/II study. For phase I, approximately 75 subjects will be recruited and will seamlessly continue to phase II recruiting 390 subject, in total 465 subjects.

In this study, DTwP-Hepatitis B-Hib-IPV (Bio Farma) vaccine will be compared to an active control (Registered DTwP-Hepatitis B-Hib Vaccine and Registered Inactivated Polio Vaccine). There are 2 formulas of DTwP-Hepatitis B-Hib-IPV Vaccine which will be used in the study. The regimen of the vaccine is 0,5 ml injected three-dose regimen with 28 days interval between doses. On the other hand, the control group will receive 0,5 ml of Registered DTwP-Hepatitis B-Hib vaccine and 0,5 ml Inactivated Bio Farma vaccine injected in three-dose regimen with 28 days interval between doses.

The safety and immunogenicity result of the Phase I study will determine the continuation of the next phase clinical trial. Clinical trial of phase II can be conducted after safety observation within 28 days after the third dose in phase I. Three hundred and ninety (390) healthy subjects aged 6-11 weeks of age will be recruited in Phase II trial.

Inclusion criteria

• Infant 6-11 weeks of age.
• Infant born after 37-42 weeks of pregnancy.
• Infant weighing more than 2.5 kg at birth.
• Father or mother, or legally acceptable representative properly informed about the study and signed the informed consent form.
• Parents will commit themselves to comply with the indications of the investigators and with the schedule of the trial.

Exclusion criteria

• Child concomitantly enrolled or scheduled to be enrolled in another trial.
• Evolving moderate or severe illness, especially infectious diseases or fever (axillary temperature ≥37.5°C on Day 0).
• Known history of allergy to any component of the vaccines.
• History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection.
• Known history of congenital or acquired immunodeficiency (including HIV infection).
• Child who has received in the previous 4 weeks of a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products or long term corticotherapy (> 2 weeks).
• Other vaccination within the 7 days prior to inclusion with the exception of BCG and poliomyelitis.
• Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives.
• Infant with a known history of diphtheria, tetanus, pertussis, Hib, hepatitis B infection.